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In recent years a strong trend towards intensified and continuous biopharmaceutical processing has gathered 
momentum, enabled by key cell culture technologies such as ATF and TFF. However, small-scale application 
has been limited to traditional benchtop bioreactor formats that are manually intensive, relatively low throughput 
and costly to operate. Automated high throughput single-use bioreactor systems have transformed fed-batch 
cell culture bioprocess development over the last decade and new capabilities to support perfusion culture in 
these micro and mini bioreactor formats could facilitate and accelerate an industry wide transition to intensified 
and continuous perfusion cell culture processes. 
 
Working in close collaboration with biopharm industry development partners, the design of the ‘ambr 250 high 
throughput’ bioreactor system has been modified to include hardware, software and single use components 
required to operate up to 24 parallel bioreactors with ATF or TFF cell retention modes. Iterative prototype testing 
with development partners has resulted in a novel ambr 250 system design capable of operating for extended 
culture durations and supporting high cell densities. In addition, a new Generation 2 ambr 15 cell culture system 
has been developed and demonstrated with technical capabilities facilitating perfusion mimic applications. Case 
studies will be presented on the utility of new ambr 15 system features for perfusion mimic (20-40M cell/ml) via 
cell settling and centrifugation methods, together with a range of industry case studies and novel performance 
data for the new ‘ambr 250 perfusion’ system (24 parallel perfusion cultures; >30d; >100M cell/ml; 0.25 vs. 5L; 
fully automated VCD control). 
 
As previously established with ambr systems for fed-batch processes, the new Generation 2 ambr 15 and ambr 
250 perfusion systems together have the potential to provide the biopharm industry with a step change in 
perfusion process development capacity, enabling high throughput bioreactor screening and DoE optimization 
approaches for accelerated perfusion process development. 
 
 
 
